Tenofovirdisoproxil
Active pharmaceutical substance formulated in Jan Aushadhi generic products for Antibiotics & Anti-Infectives treatment.
🧴 Clinical Application
Take orally once daily or twice daily at the exact same hour every single day. Strict lifelong adherence is paramount to prevent viral rebound and resistance mutation. Do not skip doses or alter timing without specialist guidance.
⚠️ Side Effects
Common: Headache, nausea, fatigue, insomnia, diarrhea, abnormal dreams (with efavirenz). Rare/Severe: Renal tubular dysfunction/Fanconi syndrome (tenofovir disoproxil), loss of bone mineral density, severe hypersensitivity (abacavir HLA-B*5701), lactic acidosis/severe hepatomegaly with steatosis, and immune reconstitution inflammatory syndrome (IRIS).
🛡️ Safety Warnings
Black box warnings: Exacerbation of Hepatitis B upon treatment discontinuation in co-infected patients. HLA-B*5701 genetic testing is mandatory prior to abacavir administration to prevent fatal hypersensitivity. Routine monitoring of renal function, bone density, viral load, and CD4 counts is essential.
Jan Aushadhi Products containing Tenofovirdisoproxil
Found 4 generic formulation(s) containing this active ingredient.
Efavirenz 600mg + Emtricitabine 200mg + Tenofovir Disoproxil Fumarate 300mg Tablets
Antiretroviral therapy (ART) formulation comprising nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase strand transfer inhibitors (INSTIs), or boosted protease inhibitors (PIs). Engineered to suppress HIV-1 viral replication to undetectable levels, halt disease progression, and restore CD4 immune function.
Emtricitabine 200mg + Tenofovir Disoproxil Fumarate 300mg Tablets
Antiretroviral therapy (ART) formulation comprising nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase strand transfer inhibitors (INSTIs), or boosted protease inhibitors (PIs). Engineered to suppress HIV-1 viral replication to undetectable levels, halt disease progression, and restore CD4 immune function.
Dolutegravir (50 Mg) + Emtricitabine (200 Mg) + Tenofovir Alafenamide (25 Mg) Tablets
Antiretroviral therapy (ART) formulation comprising nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase strand transfer inhibitors (INSTIs), or boosted protease inhibitors (PIs). Engineered to suppress HIV-1 viral replication to undetectable levels, halt disease progression, and restore CD4 immune function.
Dolutegravir (50Mg) + Lamivudine (300Mg) + Tenofovir Disoproxil Fumarate (300Mg) Tablets
Antiretroviral therapy (ART) formulation comprising nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase strand transfer inhibitors (INSTIs), or boosted protease inhibitors (PIs). Engineered to suppress HIV-1 viral replication to undetectable levels, halt disease progression, and restore CD4 immune function.
Brand Equivalents & Price Comparison
Compare Jan Aushadhi generic prices against popular commercial brands for Tenofovirdisoproxil.
| Generic Formulation | Pack Size | Jan Aushadhi Price | Commercial Brand Equivalents | Avg. Commercial Price | Savings |
|---|---|---|---|---|---|
| Efavirenz 600mg + Emtricitabine 200mg + Tenofovir Disoproxil Fumarate 300mg Tablets | 30's | ₹1031.25 | N/A | N/A | N/A |
| Emtricitabine 200mg + Tenofovir Disoproxil Fumarate 300mg Tablets | 30's | ₹984.38 | N/A | N/A | N/A |
| Dolutegravir (50 Mg) + Emtricitabine (200 Mg) + Tenofovir Alafenamide (25 Mg) Tablets | 30's in Bottle | Under Process | N/A | N/A | N/A |
| Dolutegravir (50Mg) + Lamivudine (300Mg) + Tenofovir Disoproxil Fumarate (300Mg) Tablets | 30's in Bottle | ₹650.00 | N/A | N/A | N/A |
Frequently Asked Questions (FAQ)
Get answers to common queries about Tenofovirdisoproxil generics.